Striking the right balance between risk and innovation with Marek Wasiluk

Sylvain Berthelot welcomes Dr. Marek Wasiluk, CEO of ClinMark. With a career that spans from CRA to leading a global CRO, Marek brings a unique perspective on how clinical research organizations can embrace innovation while safeguarding trial quality.

Together, they explore the fine balance between adopting new technologies and managing operational risk. Marek shares how his background in medicine, quality assurance, and clinical operations shapes his approach to implementing digital solutions that not only meet regulatory expectations but also bring real value to sponsors and patients.

Sylvain and Marek discuss why CROs must be both cautious and bold when evaluating new tools, how to build trust with clients while innovating, and the importance of curiosity and adaptability in driving meaningful change.

Tune in to hear how CROs can move beyond “shiny new objects” and take a thoughtful, balanced approach to innovation in clinical trials.

Share via

See CRScube in action

Book a demo

Explore how our platform will elevate your team and clinical trial management.

Get insights straight to your inbox

Explore our knowledge base

Stay in-the-know with regular updates and industry opinions from our expert team.

See all resources

Featured resources

Modern safety reporting in a legacy world – How cubeSAFETY compares, according to CRScube’s COO

Safety reporting is moving beyond simple adverse event collection. The future lies in intelligent risk detection and frictionless data capture.

Electronic safety reporting in clinical trials: What sponsors need to know

For sponsors and CROs, it is crucial to understand the implications of the full enforcement of ICH E2B(R3) standards, especially as it impacts both pre- and post-authorization submissions.